COVID-19 induced type 1 diabetes: A systematic review of case reports and series

Abstract

Aims

To provide an overview of reported cases of new-onset type 1 diabetes mellitus (T1D) following COVID-19 infection.

Methods

PubMed and Scopus library databases were screened for relevant case reports published between January 2020 and June 2022. Study design, geographic region or language were not restricted.

Results

Twenty studies were identified and involved 37 patients (20 [54%] male, 17 [46%] female). Median age was 11.5 years (range 8 months–33 years) and 31 (84%) patients were aged ≤17 years. Most patients (33, 89%) presented with diabetic ketoacidosis (DKA). In total, 23 (62%) patients presented at the time of positive COVID-19 testing and 14 (38%) had symptoms consistent with COVID-19 infection or a previous positive test (1–56 days). Diabetes symptomatology was provided in 22 cases and (19, 86%) reported polyuria, polydipsia, polyphagia, fatigue, or weight loss or a combination of the aforementioned in the preceding weeks (3 days–12 weeks). Of the 28 patients that had data on acute and long-term treatment, all recovered well and most were managed with basal bolus insulin regimens. Quality assessment showed that most reports were either ‘good’ or ‘moderate quality’.

Conclusions

Although uncommon, new-onset T1D is a condition healthcare professionals may expect to see following a COVID-19 infection.

Keywords

Covid-19 diabetes autoimmune diabetes diabetic ketoacidosis systematic review

Introduction

In December 2019, an atypical case of viral pneumonia was discovered in Wuhan, Hubei Province of China. The cause was a novel coronavirus strain termed, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).^1,2 Subsequently, coronavirus disease 2019 (COVID-19) has affected hundreds of millions of individuals, placed significant pressure on public health structures, and caused unprecedented socio-economic implications worldwide.^3,4

Patients infected with SARS-CoV-2 exhibit a clinical presentation that commonly includes fever, dry cough and respiratory distress.⁵ The presentation of the disease caused by the virus may also include non-respiratory manifestations such as vomiting, diarrhoea and abdominal pain, with the extent of organ involvement being unpredictable, especially long-term.^6–9 Recently, published data suggest that SARS-CoV-2 could also potentially contribute to an increase in the incidence of cases of type 1 diabetes mellitus (T1D), one of the most prevalent endocrine diseases in childhood.¹⁰ Indeed in the UK, investigators reported an 80% increase in the number of cases of T1D in children in 2020 compared with previous years, which may suggest an association between COVID-19 infection and T1D presentation.¹¹ Previous research has found that seasonal viruses can be trigger factors for T1D.^12,13 Therefore, the seasonal variation in the incidence of T1D may be partly explained by the periodic variation of viral infections.¹⁴ Similarly, COVID-19 may precipitate/accelerate the presentation of T1D or, possibly contribute to the diagnosis of previously unrecognized T1D cases as patients present as diabetic emergencies.¹⁵ The aim of our systematic review was to screen all currently available published literature and provide a complete summary of reported cases of T1D following COVID-19 infection.

Methods

Two independent [DS, KKT] searches were performed of PubMed and Scopus databases for studies published from 01 January 2020 to 30 June 2022 that provided data for new onset or exacerbation of diabetes following COVID-19 infection. Search terms included: “(COVID-19 OR COVID19 OR SARS-COV2) AND (Diabetes OR Diabetes mellitus OR DM)”. In addition, the reference lists of all included studies were checked for any potential additional publications. The study design, geographic region or language were not restricted; studies were included if they provided individual patient data. However, review articles, abstracts submitted in conferences and non-peer reviewed sources were excluded. Studies on in vitro and animal models were also excluded. The two reviewers [DS, KKT] first screened titles followed by abstracts and selected relevant studies. They independently extracted data with any disagreement settled by a third reviewer [KSK].

The following items, when available, were extracted: first author; publication date; region; gender; age; comorbidities; family history of diabetes; presenting symptoms; history of COVID-19 infection; laboratory test results; imaging findings; therapeutic management (acute and long-term).

Independent assessment of risk of bias (RoB) was performed by two authors [KSK, KKT] using the critical appraisal checklist by the Joanna Briggs Institute (JBI).¹⁶ For case studies, the assessment is based on the reporting of eight different elements: patient demographics; medical history; health status; diagnosis; intervention; post-intervention health status; unanticipated events; takeaway lessons. Depending on the availability of information for every element, the studies were scored as follows: yes; no; unclear; not/applicable.^6,16

Descriptive statistics were used to describe the demographics and clinical characteristics of the included patients. Means for continuous variables and frequencies and percentages for binary variables were used. The systematic review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) regulations.¹⁷Ethical committee approval was not required and the protocol was register in the PROSPERO online database (CRD42022338271).

Results

The initial literature search yielded 564 publications. Following removal of duplicates and the exclusions, 20 studies were eligible for the systematic review (Figure 1).^18–37 Seven of the studies were conducted in Europe, five in USA, four in North Africa, and four in Asia (Table 1). In terms of design, two studies were case series and 18 were case reports

Figure 1.

Prisma flowchart demonstrating the screening process. IPD: individual patient data.

Table 1.

Characteristics of included studies.

Author/year	Country	No.	Age,/gender	Family history of diabetes	Onset of COVID-19	Presenting symptoms	Management	Long term management
Schiaffini, 2022¹⁸	Italy	1	12y M	Nil	Before admission (3 days)	Fever Headache Osmotic symptoms (polydipsia) Weight loss	SC insulin	Basal bolus regimen
Lança, 2022¹⁹	Portugal	1	13y M	First degree relative with T1D	Before admission(7 days)	Fever Dysgeusia Abdominal pain Vomiting Diarrhoea Osmotic symptoms (polyphagia, polyuria) Fatigue Anosmia Nasal congestion Odynophagia	DKA protocol Fluid resuscitation IV insulin	Basal bolus regimen (glargine and lispro)
Lança, 2022¹⁹		2	17y F	NR	Before admission(10 days)	Altered mental status Osmotic symptoms (polydipsia, polyuria) Weight loss	DKA protocol Fluid resuscitation IV insulin	Rapid-acting insulin (lispro) Long-acting insulin (glargine)
Boboc, 2021²⁰	Romania	8	mean age:8y (1–17y) 4 M/4 F	Second degree relative with T1D(1 case)	On admission	COVID-19 infection was completely asymptomatic in four of the children, one patient presented with fever (40°C), eating refusal, and somnolence, two patients experienced vomiting, and abdominal pain and one patient was diagnosed with stomatitis	NR	NR
Hollstein, 2020²¹	UK	1	19y M	Second degree relatives with T1D and T2DM	Before admission(∼35-49 days)	Fatigue Exhaustion Osmotic symptoms (weight loss, polydipsia, nycturia) Left-sided flank pain	DKA protocol Fluid resuscitation IV insulin	SC insulin
Marchand, 2020²²	France	1	29y F	Second degree relatives with T1D and T2DM	Before admission(∼28 days)	Osmotic symptoms (polyuria–polydipsia)	Basal bolus regimen	Basal bolus regimen
Kästner, 2020²³	Germany	1	8y M	Second degree relative with T2DM	On admission	Osmotic symptoms (polyuria) Weight loss	DKA protocol Fluid resuscitation IV insulin	Basal bolus insulin regimen
Potier, 2020²⁴	France	1	31y M	NR	Before admission(5 days)	Fever Vomiting Fatigue	DKA protocol Fluid resuscitation IV insulin	SC insulin
Ambati, 2022²⁵	USA	1	10y F	T1D and T2DM	On admission	Nausea Vomiting Diarrhoea Altered mental status Osmotic symptoms (polydipsia, polyuria) Weight loss	DKA protocol Fluid resuscitation IV insulin	Rapid-acting insulin (lispro) Long-acting insulin (glargine)
Ambati, 2022²⁵		2	17y F	NR	Before admission(10 days)	Altered mental status Osmotic symptoms (polydipsia, polyuria) Weight loss	DKA protocol Fluid resuscitation IV insulin	Rapid-acting insulin (lispro) Long-acting insulin (glargine)
Nielsen-Saines, 2021²⁶	USA	1	7y M	NR	On admission	Anorexia Osmotic symptoms (polydipsia) Weight loss Abdominal pain Nausea Headache	DKA protocol Fluid resuscitation IV insulin	SC insulin regimen
Derrick, 2021²⁷	USA	1	15y F	NR	Before admission	Pruritus Hyperpigmentation Reticulated eruption on the trunk Osmotic symptoms (polydipsia, polyuria) Weight loss	NR	NR
Soliman, 2020²⁸	USA	1	8 mo M	ΝR	Before admission(2 days)	Fever Vomiting Tachypnoea	DKA protocol Fluid resuscitation IV insulin	Detemir as basal insulin and Lispro before meals
Naguib, 2020²⁹	USA	1	8y F	First degree relative with T2DM	Before admission(4 days)	Fever Rash Respiratory distress Hemodynamic instability	DKA protocol Fluid resuscitation IV insulin Aspirin Antibiotics, epinephrine and vasopressin infusions, furosemide infusion, IVIG 2 g/kg, infliximab, methylprednisolone (multisystem inflammatory syndrome due to COVID-19)	Total daily insulin 1.1 unit/kg/day and full dose metformin.
Aly, 2022³⁰	Egypt	1	13y M	NR	On admission	Fever Sore throat Dyspnoea Altered mental status Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin Steroids, enoxaparin, aspirin (multisystem inflammatory syndrome), bicarbonate (AKI)	Basal bolus regimen
		2	10y F	NR	On admission	Fever (39°C) Altered mental status Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin Steroids, enoxaparin, aspirin (multisystem inflammatory syndrome)	Basal bolus regimen
		3	6y M	NR	On admission	Fever (39.5°C) Abdominal pain Vomiting Myalgia Fatigue	DKA protocol Fluid resuscitation IV insulin Steroids, enoxaparin, aspirin (multisystem inflammatory syndrome)	Basal bolus regimen
		4	13y F	NR	On admission	Fever (39°C) Dyspnoea Altered mental status Weight loss	DKA protocol Fluid resuscitation IV insulin Steroids, enoxaparin, aspirin IVIG furosemide, captopril (multisystem inflammatory syndrome), bicarbonate (AKI)	Basal bolus regimen
		5	10y F	DM (type not reported)	On admission	Fever (38.5°C) Abdominal pain Vomiting Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin Steroids, enoxaparin, aspirin IVIG, furosemide, captopril, anakinra (multisystem inflammatory syndrome)	Basal bolus regimen
		6	11y F	NR	On admission	Fever (40°C) Abdominal pain Vomiting Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin Steroids, enoxaparin, aspirin IVIG, furosemide, captopril, anakinra (multisystem inflammatory syndrome)	Basal bolus regimen
Alfishawy, 2021³¹	Egypt	1	17y M	NR	On admission	Fever Palpitations Cough	DKA protocol Fluid resuscitation IV insulin Azithromycin, hydroxychloroquine(COVID-19)	SC insulin
Chekhlabi, 2021³²	Morocco	1	4y F	Nil	Before admission(15 days)	Somnolence Polypnea Abdominal pain Flu-like syndrome Osmotic symptoms (polyuria, polydipsia, polyphagia) Vomiting Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin	Insulin glargine and insulin aspart as mealtime insulin
Chekhlabi, 2021³²		2	7y M	Nil	On admission	Osmotic symptoms (polyuria, polydipsia) Vomiting Abdominal pain Polypnea Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin	Insulin glargine and insulin aspart as mealtime insulin
Benyakhlef, 2021³³	Morocco	1	3y M	Second degree relatives with T2DM	On admission	Acute dyspnoea Asthenia Vomiting Fever Osmotic symptoms (polyuria, polydipsia) Weight loss	DKA protocol Fluid resuscitation IV insulin Antipyretics (COVID-19)	Basal bolus insulin regimen
Sarwani, 2021³⁴	Bahrain	1	23y M	Nil	Before admission(15 days)	Fatigue Osmotic symptoms (polydipsia) Weight loss Myalgia	DKA protocol Fluid resuscitation IV insulin	SC insulin regimen
		2	27y F	First degree relative with T2D	Before admission(1 day)	Fever Vomiting Dry cough Dyspnoea Osmotic symptoms (polyuria, polydipsia)	DKA protocol Fluid resuscitation IV insulin Ceftriaxone and azithromycin (LRTI)	Insulin glargine 20 units once daily and insulin aspart 10 units three times daily
		3	14y M	Nil	Before admission(3 days)	Fever Abdominal pain Nausea Vomiting	DKA protocol Fluid resuscitation IV insulin	Insulin glargine 20 units once daily and insulin aspart 15 unitsthree times daily
Rabizadeh, 2020³⁵	Iran	1	16y M	Second degree relative with T2DM	On admission	Fever Nausea Abdominal pain Osmotic symptoms (polyuria, polydipsia) Weight loss Fatigue	DKA protocol Fluid resuscitation IV insulin Hydroxychloroquine, lopinavir/ritonavir(COVID-19)	Basal bolus insulin regimen
Daniel, 2020³⁶	India	1	15y F	NR	On admission	Fever Abdominal pain Vomiting	DKA protocol Fluid resuscitation IV insulin Hydroxychloroquine (COVID-19)	Basal bolus regimen
Ishii, 2021³⁷	Japan	1	33y F	First degree relative with T2DM	Before admission (2 days)	Osmotic symptoms (polyuria, polydipsia) Dyspnoea Fatigue	DKA protocol Fluid resuscitation IV insulin Favipiravir	Basal bolus regimen

Abbreviations: M, male; F, female; SC, subcutaneous; T1D, type 1 diabetes; T2DM, type 2 diabetes mellitus; NR, not recorded; DKA, Diabetic Ketoacidosis; LRTI, lower respiratory tract infection

In total, there were 37 cases of new onset T1D. Of these, 23 (62%) patients presented at the time of positive polymerase chain reaction (PCR) test, or rapid antigen COVID-19 testing. The remaining 14 (38%) patients had symptoms consistent with COVID-19 infection or had a positive COVID-19 test previously (i.e., 1–56 days prior to diagnosis of T1D) (Table 1).

Of the 37 patients, 20 (54%) were male and 17 (46%) were female. Median age was 11.5 years (range 8 months to 33 years) and 31 (84%) patients were aged ≤17 years. Details of medical history were provided for 34 patients and most (29, 85%) had no co-comorbidities. Co-morbidities included obesity (2, 5%), coeliac disease (1, 3%), gestational diabetes (1, 3%) and hypothyroidism (1, 3%). Information about relevant family history was provided for 24 patients, of whom 12 (50%,) had at least one family member with a history of either type 1 or type 2 diabetes (Table 1).

Data regarding onset of diabetes symptomatology was provided in 22 cases with the majority (19, 86%) reporting polyuria, polydipsia, polyphagia, fatigue, or weight loss or more typically a combination of the above in the preceding weeks (i.e., 3 days to 12 weeks). In the three (14%) remaining cases, the patients reported that they had no common clinical features of diabetes prior to diagnosis.

Most patients (33/37, 89%) presented with diabetic ketoacidosis (DKA). The most common symptoms were fever (19/37, 51%), weight loss (18/37, 49%), nausea/vomiting (15/37, 41%), osmotic symptoms (16/37, 43%), fatigue (13/37, 35%) and abdominal pain (12/37, 32%) (Table 1). With the exception of two cases where data were not provided,^24,27 all patients had levels of haemoglobin A1c (HbA1c) >6.5%. For the 28 cases where blood glucose was recorded, all patients had blood levels >250 mg/dl (Table 2).

Table 2.

Laboratory results and imaging findings.

Authoryear	Case	Blood results (normal values)	Diabetes antibodies (normal values)	HLA	Imaging
Schiaffini, 2022¹⁸	1	Glu: >400 mg/dl BG: pH 7.34, BE −5.8 mEq/l, HCO3⁻: 19.5 mEq/l Ketones: NR HbA1c: 122 mmol/l (13.3%) C-peptide 2.47 ng/ml (1.10–4.40) Lipase and pancreatic amylase, normal	GAD-65: Positive IAA: Negative IA2: Negative	Positive DRB103 DQB102 and DQA105	NR
Lança, 2022¹⁹	1	Glu: 517mg/dl BG: pH 7.18, HCO3⁻: 11.6mmol/l Ketones: 5.8 mmol/l (blood) HbA1c: 144 mmol/l (15.3%) C peptide: 0.4 ng/ml (0.9–7.1ng/ml)	GAD-65: Positive 6.9 U/ml (>1,0)	NR	NR
Lança, 2022¹⁹	2	Glu: 552 mg/dl BG: pH 7.21, HCO3⁻: 13.1 mmol/l Ketones: 7 mmol/l (blood) HbA1c: 112 mmol/l (12.4%) C peptide: <0.1ng/ml (0.9–7.1ng/ml)	GAD-65: Positive 1.3 U/ml (>1,0)	NR	NR
Boboc, 2021²⁰	1	Glu: NR BG: pH 7.09 Ketones: NR HbA1C: 90 mmol/l (10.4%)	NR	NR	NR
	2	Glu: NR BG: pH 7.22 Ketones: NR HbA1C: 110 mmol/l (12.2%)	NR	NR	NR
	3	Glu: NR BG: pH 7.20 Ketones: NR HbA1C: 130 mmol/l (14%)	NR	NR	NR
	4	Glu: NR BG: pH 7.13 Ketones: NR HbA1C: 115 mmol/l (12.7%)	NR	NR	NR
	5	Glu: NR BG: pH 7.13 Ketones: NR HbA1C: 93 mmol/l (10.7%)	NR	NR	NR
	6	Glu: NR BG: pH 6.99 Ketones: NR HbA1C: 99 mmol/l (11.2%)	NR	NR	NR
	7	Glu: NR BG: pH 7.36 Ketones: NR HbA1C: 113 mmol/l (12.5%)	NR	NR	NR
	8	Glu: NR BG: pH 7.22 Ketones: NR HbA1C: 127 mmol/l (13.8%)	NR	NR	NR
Hollstein, 2020²¹	1	Glu: 552 mg/dl BG: pH 7.1 Ketones: positive (urine) HbA1c: 160.1 mmol/l (16.8%) C-peptide: 0.62 µg/l (1.1–4.4)	ICA: negative GAD-65: <5 IU/ml (<10) IAA: <0.1 IU/ml (<0.4) IA2: <10 IU/ml (<10) Anti-ZnT8: < 10 IU/ml (<15)	PositiveHLA DR1-DR3-DQ2	NR
Marchand, 2020²²	1	Glu: 369 mg/dl BG: HCO3⁻: 26 mmol/l Ketones: 0.7 mmol/l HbA1c: 105.5 mmol/l (11.8%) C-peptide: 0.07 pmol/ml (0.37–1.47)	GAD-65: 93 UI/ml (<17) IAA: negative IA2: negative ZnT8: negative	NR	CT abdomen: Normal pancreatic
Kästner, 2020²³	1	Glu: 369 mg/dl BG: NR Ketones: >15 mmol/l (urine) HbA1c: 103.3 mmol/l (11.6%) C-peptide: 0.80 µg/l (0.49–5.52)	ICA: negative GAD-65: 1172 (<10 IU/ml) IAA: 4.81 U/ml (<0.4) IA2: >4000 IU/ml (<19) ZnT8-Ab: negative	Positive HLA DR3-DQB102 and DR4-DQB103:02	NR
Potier, 2020²⁴	1	Glu: 426 mg/dl BG: pH 7.28, HCO3⁻: 8 mmol/l Ketones: 5.2 mmol/l (blood) HbA1c: NR	ICA: negative GAD-65: 118.4 U/ml IA2: negative ZnT8: 304.2 U/ml	NR	CT Thorax: basal bilateral ground-glass opacities and air-space consolidation
Ambati, 2022²⁵	1	Glu: 448 mg/dl BG: pH 7.08 (7.32 – 7.43), HCO3⁻: 8 mEq/l (21-30), AG: 28 mEq/l (6 – 12) Ketones: 4+ (urine) HbA1c: 107 mmol/l (11.9%)	ICA: Negative GAD-65: Negative IAA: Negative	NR	NR
Ambati, 2022²⁵	2	Glu: 2136 mg/dl BG: pH 7.07, HCO3⁻: 8 mEq/l, AG: 31 mEq/l Ketones: 1+ (urine) HbA1c: 138 mmol/l (14.8%)	NR	NR	NR
Nielsen-Saines, 2021²⁶	1	Glu: 470 mg/dl BG: pH 7.01, HCO3⁻: 3.5 mEq/l, AG: 32 mmol/l Ketones: 2+ (urine) HbA1c: 138 mmol/l (14.8%) C-peptide: 0.2 (1.1-4.3 ng/ml)	GAD-65: >250 IU/ml (0-5) IAA: <0.4 U/ml IA2: >120 U/ml (0-7.4) ZnT8: 140 U/ml (>15)	NR	CXR: Normal
Derrick, 2021²⁷	1	NR	NR	NR	NR
Soliman, 2020²⁸	1	Glu: 571 mg/dl BG: pH 7.08, HCO3⁻: 2 mmol/l, BE: -20.5 mEq/l Ketones: β-Hydroxybutyric acid: 6.4 mmol/l (<0.3) HbA1c: 69 mmol/l (8.5%) C-Peptide: 0.43 ng/ml (0.50-5.50) Insulin: 2.7 µUI/ml (0.8-24.3)	GAD-65: 34.9 IU/ml (<5)	NR	CXR: Normal
Naguib, 2020²⁹	1	Glu: 429 mg/dl BG: pH 7.3, HCO3⁻: 14 mEq/l Ketones: >160 mg/dl (urine) HbA1c: 107.7 mmol/l (12%)	GAD-65: <5 IU/ml IAA: <0.4 U/ml IA2: <0.02 nmol/l	NR	CT head: NormalEcho: mildly reduced systolic function with dilation of the left anterior descending artery CXR: pleural effusion
Aly, 2022³⁰	1	Glu: 750 mg/dl BG: pH 6.7, HCO3⁻: 3 mEq/l Ketones: 5+ (urine) HbA1c: 112 mmol/l (12.4%)	NR	NR	NR
	2	Glu: 680 mg/dl BG: pH 6.8, HCO3⁻: 3.3 mEq/l Ketones: 3+ (urine) HbA1c: 108 mmol/l (12%)	NR	NR	NR
	3	Glu: 630 mg/dl BG: pH 6.9, HCO3⁻: 3.1 mEq/l Ketones: 4+ (urine) HbA1c: 98 mmol/l (11.1%)	NR	NR	NR
	4	Glu: 630 mg/dl BG: pH 6.8, HCO3⁻: 4.1 mEq/l Ketones: 4+ (urine) HbA1c: 97 mmol/l (11%)	NR	NR	NR
	5	Glu: 820 mg/dl BG: pH 6.7, HCO3⁻: 3.6 mEq/l Ketones: 4+ (urine) HbA1c: 99 mmol/l (11.2%)	NR	NR	NR
	6	Glu: 690 mg/dl BG: pH 6.9, HCO3⁻: 5.8 mEq/l Ketones: 4+ (urine) HbA1c: 160 mmol/l (17%)	NR	NR	NR
Alfishawy, 2021³¹	1	Glu: 566 mg/dl BG: pH 6.8 Ketones: + (urine) HbA1c: 137 mmol/l (14.7%) Amylase: 285 U/l (<100), Lipase 273 U/l (<60)	ICA: Positive GAD-65: Positive	NR	CT thorax: ground-glass opacities, abdominal cuts: dilated intrahepatic biliary radicles with pancreatic loculations suggestive of pancreatitis
Chekhlabi, 2021³²	1	Glu: 390 mg/dl BG: pH 6.8 Ketones: acetone + (urine) HbA1c: 105 mmol/l (11.8%)	ICA: positive (280 IU/ml) GAD-65: positive (59 IU/ml)	NR	CXR: Normal
Chekhlabi, 2021³²	2	Glu: 423 mg/dl BG: NR Ketones: large amount in urine HbA1c: 89 mmol/l (10.3%)	ICA: negative (8 IU/ml) GAD-65: negative (3 IU/ml)	NR	CXR: Normal
Benyakhlef, 2021³³	1	Glu: 300 mg/dl BG: pH 7.25, HCO3⁻: 13.2 mEq/l Ketones: 3+ ketones (urine) HbA1c: 89 mmol/l (10.3%)	GAD-65: 60 IU/mL (<5)	NR	CT thorax: bilateral ground-glass opacities
Sarwani, 2021³⁴	1	Glu: 738 mg/dl BG: pH 7.19, HCO3⁻: 15.7 mmol/l, AG: 23 mEq/l Ketones: + (blood) HbA1c: 138 mmol/l (14.8%)	NR	NR	CXR: Normal
	2	Glu: 432 mg/dl BG: pH 7.15, HCO3⁻: 10.3 mmol/l, AG: 21 mEq/l Ketones: + (blood) HbA1c: 57 mmol/l (7.4%)	NR	NR	CXR: bilateral infiltrates
	3	Glu: 677 mg/dl BG: pH 6.9, HCO3⁻: 7 mmol/l, AG: 28 mEq/l Ketones: + (blood) HbA1c: 110 mmol/l (12.2%)	IAA: 1 U/ml (<0.4) IA2: 112.3 IU/ml (<10)	NR	CXR: Normal CT abdomen: Normal
Rabizadeh, 2020³⁵	1	Glu: 512 mg/dl BG: pH 6.95, HCO3⁻: 8 mEq/l Ketones: 3+ (urine) HbA1c: 117.5 mmol/l (12.9%) C-peptide: 0.25 ng/ml (<0.78)	NR	NR	CT thorax: Normal
Daniel, 2020³⁶	1	Glu: 414 mg/dl BG: pH 6.9, HCO3⁻: 2 mEq/l Ketones: 4+ (urine) HbA1c: 124 mmol/l (13.5%)	GAD -65: negative*	NR	CXR: low volume lung with mild bilateral haziness
Ishii, 2021³⁷	1	Glu: 638 mg/dl BG: pH 6.74, HCO3-: 4.8 mmol/l, AG: 27.2 mmol/l Urine ketones: 3+ HbA1c: 148.1 mmol/l (15.7%) C-peptide: 0.41 ng/ml (0.80–2.50)	GAD-65: 27.4 U/ml (<5) IAA<0.4 U/ml IA2: 15 U/ml (<0.6)	NR	CT chest: consolidation in the posterior lobe, air bronchogram and a reticular pattern

Abbreviations: Glu, glucose; BG, blood glucose; BE, base excess; HCO3; bicarbonate; HbA1c, haemoglobin A1c; NR, not recorded; IAA, insulin autoantibodies; ICA, islet-cell antibodies; ZnT8, Zinc transporter 8; HLA, Human Leukocyte Antigen; CT, computed tomography; CTX, chest X ray;

Diabetes autoantibodies (i.e., islet cell cytoplasmic autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase antibodies (GADA), insulinoma-associated-2 autoantibodies (IA-2A) and Zinc Transporter 8 autoantibodies (ZnT8A) were reported for 18 patients, of whom 13 (72%) had at least one positive result (Table 2). Results of human leukocyte antigen (HLA) typing were only provided in three cases. Similarly, imaging results were only available from a few patients (9, 24%) who underwent computed tomography (CT) scans or chest X rays (Table 2).

Data on treatment in the acute and long-term settings were provided for 28 patients (Table 1). In the majority of cases, IV fluids and insulin were the mainstay of treatment in the acute setting (26/28, 93%); the remaining two (7%) patients received subcutaneous insulin.^18,22 For long-term treatment, all 28 patients received long term insulin regimens and one patient also received metformin.

Quality assessment of the eligible studies using the JBI critical appraisal tool for case studies, showed that most reports could be graded as either ‘good’ or ‘moderate quality’ (Table 3). However, only one report attained a perfect score.²⁹ Most reports only achieved 50% of the quality criteria and three reports^20,27,31did not meet at least 50% of the criteria and were classified as high risk of bias. Across the 20 reports, the domain most commonly assessed as ‘not available’ was Q7 (unanticipated events during the admission).

Table 3.

Quality assessment of the included studies.

Reference	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8
Schiaffini, 2022¹⁸	●	●	●	●	○	○	◌	●
Lança, 2022¹⁹	●	●	●	●	○	●	◌	●
Bococ, 2021²⁰	ᴓ	○	○	●	○	○	○	●
Hollstein, 2020²¹	ᴓ	●	●	●	●	●	◌	●
Marchand, 2020²²	●	●	○	ᴓ	●	○	◌	●
Kästner, 2020²³	ᴓ	○	●	●	●	●	◌	●
Potier, 2020²⁴	●	●	○	●	●	●	◌	●
Ambati, 2022²⁵	●	○	●	●	●	●	◌	●
Nielsen-Saines, 2021²⁶	●	●	ᴓ	●	●	●	◌	●
Derrick, 2021²⁷	●	●	○	●	○	○	◌	ᴓ
Soliman, 2020²⁸	●	●	●	●	●	●	◌	●
Naguib, 2020²⁹	●	●	●	●	●	●	●	●
Aly, 2022³⁰	ᴓ	○	○	●	●	●	◌	●
Alfishawy, 2021³¹	ᴓ	●	○	ᴓ	●	ᴓ	◌	●
Chekhlabi, 2021³²	ᴓ	●	ᴓ	○	●	●	◌	●
Benyakhlef, 2021³³	●	ᴓ	●	●	●	●	◌	●
Sarwani, 2021³⁴	ᴓ	●	●	●	●	●	●	●
Rabizadeh, 2020³⁵	ᴓ	●	●	●	ᴓ	ᴓ	◌	●
Daniel, 2020³⁶	ᴓ	●	ᴓ	●	●	●	●	●
Ishii, 2020³⁷	○	○	●	●	●	●	●	●

Q1: Were patient’s demographic characteristics clearly described? Q2: Was the patient’s history clearly described and presented as a timeline? Q3: Was the current clinical condition of the patient on presentation clearly described? Q4: Were diagnostic tests or methods and the results clearly described? Q5: Was the intervention(s) or treatment procedure(s) clearly described? Q6: Was the post-intervention clinical condition clearly described; Q7: Were adverse events (harms) or unanticipated events identified and described? Q8: Does the case report provide takeaway lessons?

● = Yes; ○ = No; ᴓ = Unclear; ◌ = Not Available.

Available from, https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Case_Reports2017_0.pdf

Discussion

COVID-19 infection is a disease associated with a plethora of clinical manifestations. Emerging evidence suggests a potential link between COVID-19 and the development or exacerbation of T1D.^10,11,15 In this systematic review, we comprehensively examined literature published from 01 January 2020 to 30 June 2022 to provide a current overview of reported cases of T1D following infection with SARS-CoV-2. We identified 20 reports, that included data from 37 patients for whom T1D had been reported at the time or following a COVID-19 infection. There were slightly more male than female patients and most were aged 17 years or younger. A majority presented with DKA, which was managed acutely with IV fluids and insulin therapy. For patients where long-term data were provided, they recovered well and most were managed with basal bolus insulin regimens. Our findings are consistent with previous systematic reviews on COVID-19 infection and T1D and, other autoimmune disorders such as Graves’ disease and nephrotic syndrome, that also observed a male dominance.^38–40 In addition, most of our patients were young, and, as previously reported, DKA is more common in children.⁴¹

Type 1 diabetes results from the autoimmune destruction of beta cells in the pancreas with genetic and environmental factors precipitating the disease onset.⁴² Viruses, such as influenza, parainfluenza, human herpesvirus 6 and enteroviruses are considered as triggers of autoimmune T1D in genetically susceptible individuals and are known to precipitate diabetic emergencies, such as DKA in patients with pre-existing diabetes, or even unmask latent disease.^43,44 DKA is more common in children and is caused by total or partial insulin deficiency, which favours the production of ketones and requires urgent treatment.^41,45 The preclinical period that precedes disease onset is long and it has been suggested that infectious pathogens may enhance self-antigen presentation, resulting in the involvement of different autoantigens.^46,47

Evidence of the impact of SARS-CoV-2 on new-onset T1D is conflicting. For example, one study conducted in the UK in 30 children up to the age of 16 years with new-onset T1D and DKA, found an evident increase during the pandemic and their results were based on confirmation of infection with testing or evidence of exposure.⁴⁸ Similarly, a 12-month cross sectional study conducted in the USA from March 2020 to March 2021, found a significant increase in DKA at the time of T1D diagnosis and a 57% increase from the previous year in cases among children.⁴⁹ In addition, a metanalysis on the risk of T1D and DKA in paediatric patients with T1D between the COVID-19 pre-pandemic and pandemic periods, concluded that during the first year of the COVID-19 pandemic the incidence of worldwide paediatric new-onset T1D, DKA, and severe DKA increased by 10%, 25%, and 20%, respectively.⁵⁰ In a study from Tunisia, that investigated the incidence of new onset DKA between March 2018 and February 2022, investigators reported a 48% increase during the pandemic with the frequency of T1D and T2D rising by 50% and 40% respectively.⁵¹ By contrast, a study from Belgium found that the prevalence of anti-SARS-CoV-2 antibodies in people of the same age with new-onset T1D was similar to that found in children without diabetes.⁵² Nevertheless, retrospective data from 27,292,879 patients from a national US database (Cerner Real-World Data) showed that COVID-19 diagnosis was associated with a significantly increased risk of new-onset T1D with specific ethnicities being more susceptible.⁵³ The investigators also reported that in patients with pre-existing T1D, the risk of developing DKA was significantly increased following COVID-19 diagnosis.

Reduced access to care during the pandemic may be a contributing factor related to the increase in cases with new-onset T1D presenting as DKA. In addition, lifestyle changes during the lockdowns, which included reduced physical activity and weight gain, could have also contributed to the increase in diabetes and DKA. However, SARS-CoV-2 infection may affect the pathogenesis of autoimmune diabetes. For example, it is well recognised that angiotensin converting enzyme 2 (ACE-2) is the entry point of SARS-CoV-2 to several organs including the pancreas, which supports the theory of direct injury.⁵⁴ ACE-2 is downregulated after endocytosis of SARS-Cov2, which subsequently leads to increased action of angiotensin II, a putative mechanism that could contribute to abnormal insulin secretion.^55,56 Moreover, SARS-CoV-2 antibodies may trigger inflammatory destruction of beta-cells.⁵⁷ Cytokines that play an integral role in the course of the infection, increase the ACE-2 expression in beta-cells and thus their susceptibility to the virus.⁵⁷ Interestingly, interleukin-6 is increased in both DKA and COVID-19 and has been suggested as a potential prognostic factor.⁵⁸ There is some evidence to suggest that following initial insulin dependency, some patients that present with new onset diabetes and COVID-19 are adequately controlled on oral antihyperglycemic medications several months later, suggesting a clinical picture more in line with ketosis prone diabetes.^59,60 However, data from our systematic review of 20 case reports involving 37 patients showed that HbA1c levels were increased in all patients and most tested positive for COVID-19 shortly before, or at the time of admission, and so we can assume that SARS-CoV-2 was a precipitating factor of disease onset similar to other viral infections rather than a causative factor.

To the best of our knowledge, our study is the first to construct a systematic review of the association between COVID-19 and onset or exacerbation of T1D. Our findings from 20 case reports, categorised as low risk of bias and satisfactory assessment based on case report quality criteria, are consistent with previous literature. However, there were some limitations. For example, only two databases were screened. In addition, papers were only included if they provided individual patient data. In addition, details on demographic and clinical characteristics were insufficiently reported in approximately half of the 20 studies and three did not meet >50% of the quality criteria and were considered high risk of bias. Therefore, more studies are required. Indeed, to investigate and identify a potential link between COVID-19 infection and the development or exacerbation of T1D, prospectively designed and large cohort studies are required together with epidemiological studies using extensive data from the years following the pandemic.

In summary, COVID-19 may accelerate the presentation of T1D or possibly unmask previously undiagnosed cases in a similar manner to other seasonal viruses.^53,54 New onset T1D is possibly a condition physicians and other healthcare professionals may expect to see in patients following COVID-19 infection and the early recognition of the disorder is important for the optimal management of these patients.

Supplemental Material

sj-pdf-1-imr-10.1177_03000605231210403 - Supplemental material for COVID-19 induced type 1 diabetes: A systematic review of case reports and series

Supplemental material, sj-pdf-1-imr-10.1177_03000605231210403 for COVID-19 induced type 1 diabetes: A systematic review of case reports and series by Dimitra Stathi, Konstantinos Katsikas Triantafyllidis, Marina Zafeiri, Janaka Karalliedde and Konstantinos S. Kechagias in Journal of International Medical Research

Footnotes

Declaration of conflicting interests

The authors declare that there are no conflicts of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Dimitra Stathi

References

Stratton

Tang

YW.

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020; 92: 401–402.

Yang

, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475–481.

Giannos

Kechagias

Katsikas Triantafyllidis

, et al. Spotlight on early COVID-19 research productivity: a 1-year bibliometric analysis. Front Public Health 2022; 10: 811885.

Delardas

Kechagias

Pontikos

, et al. Socio-Economic Impacts and Challenges of the Coronavirus Pandemic (COVID-19): An Updated Review. Sustainability 2022; 14: 9699. Available from https://doi.org/10.3390/su14159699

Tian

Lou

, et al. Characteristics of COVID-19 infection in Beijing. J Infect 2020; 80: 401–406.

Giannos

Katsikas Triantafyllidis

Geropoulos

, et al. Persistent Hiccups as an Atypical Presentation of SARS-CoV-2 Infection: A Systematic Review of Case Reports. Frontiers in Neurology 2022; 13: 819624.

Katsikas Triantafyllidis

Giannos

Mian

, et al. Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports. Vaccines (Basel) 2021; 9: 1013.

Triantafyllidis

Giannos

Stathi

, et al. Graves ‘disease following vaccination against SARS-CoV-2: A systematic review of the reported cases. Front Endocrinol (Lausanne) 2022; 13: 938001.

Patel

Nicolae

Geropoulos

, et al. Pneumomediastinum in the COVID-19 era: to drain or not to drain? Monaldi Arch Chest Dis 2022; 93(2).

10.

Usher-Smith

Thompson

Sharp

, et al. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. BMJ 2011; 343: D4092.

11.

Woodger

Regan

, et al. Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey. BMJ Paediatr Open 2020; 4: E000884.

12.

Yoon

Austin

Onodera

, et al. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979; 300: 1173–1179.

13.

Jun

Yoon

JW.

A new look at viruses in type 1 diabetes. ILAR journal 2004; 45: 349–374. Available from https://doi.org/10.1093/ilar.45.3.349

14.

Watad

Azrielant

Bragazzi

, et al. Seasonality and autoimmune diseases: the contribution of the four seasons to the mosaic of autoimmunity. J Autoimmun 2017; 82: 13–30.

15.

Chee

SJH

Yeoh

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 2020; 164: 108166.

16.

Munn

Aromataris

Tufanaru

, et al. The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc 2019; 17: 36–43.

17.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021; 88: 105906.

18.

Schiaffini

Campana

Deodati

, et al. SARS-CoV-2 infection as possible downstream disease precipitator in autoantibody-positive insulin-dependent diabetes mellitus: a case report. Ital J Pediatr 2022; 48: 33.

19.

Lança

Rodrigues

Diamantino

, et al. COVID-19 in two children with new-onset diabetes. BMJ Case Rep 2022; 15: e247309.

20.

Boboc

Novac

Ilie

, et al. The impact of SARS-CoV-2 pandemic on the new cases of T1DM in children. A single-centre cohort study. J Pers Med 2021; 11: 551.

21.

Hollstein

Schulte

Schulz

, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab 2020; 2: 1021–1024.

22.

Marchand

Pecquet

Luyton

Type 1 diabetes onset triggered by COVID-19. Acta Diabetol 2020; 57: 1265–1266.

23.

Kästner

Harsch

IA.

COVID-19 infection as a trigger for new-onset type 1 diabetes in a susceptible individual–or just coincidence?

GMS Hyg Infect Control 2021; 16: Doc17.

24.

Potier

Julla

Roussel

, et al. COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. Diabetes Metab 2021; 47: 101162.

25.

Ambati

Mihic

Rosario

, et al. New-onset type 1 diabetes in children with SARS-CoV-2 infection. Cureus 2022; 14: e22790.

26.

Nielsen-Saines

Olivera

, et al. Case report: insulin-dependent diabetes mellitus and diabetic keto-acidosis in a child with COVID-19. Front Pediatr 2021; 9: 628810.

27.

Derrick

Mazori

Heilman

, et al. Prurigo pigmentosa and new‐onset type 1 diabetes in a black female patient testing positive for SARS‐CoV‐2 IgG. Br J Dermatol 2021; 184: e5.

28.

Soliman

Al-Amri

Ellithy

, et al. Newly-onset type 1 diabetes mellitus precipitated by COVID-19 in an 8-month-old infant. Acta Biomed 2020; 91(3): ahead of print.

29.

Naguib

Raymond

Vidmar

AP.

New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19. J Pediatr Endocrinol Metab 2021; 34: 147–150.

30.

Aly

Fouda

Kotby

, et al. COVID-19–Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series. Diabetes Care 2022; 45: 983–989.

31.

Alfishawy

Nassar

Mohamed

, et al. New-onset type 1 diabetes mellitus with diabetic ketoacidosis and pancreatitis in a patient with COVID-19. Sci Afr 2021; 13: e00915.

32.

Chekhlabi

Haoudar

Echcharii

, et al. New-Onset diabetes with ketoacidosis precipitated by COVID-19 in children: a report of two cases. Case Rep Pediatr 2021; 2021: 5545258.

33.

Benyakhlef

Abdellaoui

Tahri

, et al. Diabetic ketoacidosis at onset of pediatric type-1 diabetes triggered by Covid-19: an original case report. Cureus 2021; 13: e13958.

34.

Sarwani

Al Saeed

Taha

, et al. New-onset diabetes mellitus presenting as diabetic ketoacidosis in patients with COVID-19: A case series. Cureus 2021; 13: e16290.

35.

Rabizadeh

Hajmiri

Rajab

, et al. Severe diabetic ketoacidosis and coronavirus disease 2019 (COVID-19) infection in a teenage patient with newly diagnosed diabetes. J Pediatr Endocrinol Metab 2020; 33: 1241–1243.

36.

Daniel

Gadhiya

Parikh

, et al. COVID-19 in a child with diabetic ketoacidosis: an instigator, a deviator or a spectator. Indian Pediatr 2020; 57: 969–970.

37.

Ishii

Suwanai

Saito

, et al. A case of diabetic ketoacidosis in a patient with COVID‐19 and newly diagnosed type 1 diabetes. Clin Case Rep 2021; 9: e04881.

38.

Blohmé

Nyström

Arnqvist

, et al. Male predominance of type 1 (insulin-dependent) diabetes mellitus in young adults: results from a 5-year prospective nationwide study of the 15–34-year age group in Sweden. Diabetologia 1992; 35: 56–62.

39.

Tutal

Ozaras

Leblebicioglu

Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis 2022; 47: 102314.

40.

Cancarevic

Nassar

Medina

, et al. Nephrotic syndrome in adult patients with COVID-19 infection or post COVID-19 vaccine: a systematic review. Cureus 2022; 14: E29613.

41.

EL-Mohandes

Yee

Bhutta

, et al. Pediatric Diabetic Ketoacidosis. [Updated 2023 Apr 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470282/.

42.

Gillespie

KM.

Type 1 diabetes: pathogenesis and prevention. CMAJ 2006; 175: 165–170.

43.

Roivainen

Rasilainen

Ylipaasto

, et al. Mechanisms of Coxsackievirus-Induced Damage to Human Pancreaticβ-Cells. J Clin Endocrinol Metab 2000; 85: 432–440.

44.

Schneider

Von Herrath

MG.

Potential viral pathogenic mechanism in human type 1 diabetes. Diabetologia 2014; 57: 2009–2018.

45.

Hadil

Eman

Bashayer Zuhair

, et al. Diabetic ketoacidosis and new onset diabetes mellitus precipitated by COVID-19 infection. JOJ Case Stud 2020; 11: 555815. Available from https://juniperpublishers.com/jojcs/JOJCS.MS.ID.555815.php

46.

Velluzzi

Secci

Sepe

, et al. Prediction of type 1 diabetes in Sardinian schoolchildren using islet cell autoantibodies: 10-year follow-up of the Sardinian schoolchildren type 1 diabetes prediction study. Acta Diabetol 2016; 53: 73–79.

47.

Benoist

Mathis

Retrovirus as trigger, precipitator or marker?

Nature 1997; 388: 833–834.

48.

Unsworth

Wallace

Oliver

, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the UK. Diabetes Care 2020; 43: E170–E171.

49.

Gottesman

Tanaka

, et al. Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. JAMA Pediatr 2022; 176: 414–415.

50.

Rahmati

Keshvari

Mirnasuri

, et al. The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: a systematic review and meta‐analysis. J Med Virol 2022; 94: 5112–5127.

51.

Gorchane

Ach

Sahli

, et al. Uncovering the alarming rise of diabetic ketoacidosis during COVID-19 pandemic: a pioneer African study and review of literature. Front Endocrinol (Lausanne) 2023; 14: 1234256.

52.

Messaaoui

Hajselova

Tenoutasse

Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium. J Pediatr Endocrinol Metab 2021; 34: 1319–1322.

53.

Qeadan

Tingey

Egbert

, et al. The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: A nationwide cohort from the US using the Cerner Real-World Data. PLoS One 2022; 17: E0266809.

54.

Gheblawi

Wang

Viveiros

, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020; 126: 1456–1474.

55.

Bornstein

Dalan

Hopkins

, et al. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol 2020; 16: 297–298.

56.

Carlsson

Berne

Jansson

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127–133.

57.

Fignani

Licata

Brusco

, SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. Front Endocrinol (Lausanne) 2020; 11: 596898.

58.

Vaduganathan

Vardeny

Michel

, et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. New England Journal of Medicine 2020; 382: 1653–1659.

59.

Rubino

Amiel

Zimmet

, et al. New-onset diabetes in Covid-19. N Engl J Med 2020; 383: 789–790.

60.

Kuchay

Reddy

Gagneja

, et al. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. Diabetes Metab Syndr 2020; 14: 2039–2041.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.57 MB